Compositions are provided that target biological therapeutic agents to mucosal defects in the gastrointestinal tract by means of antacid mucosal protective agents that bind selectively to such defects.

Obesity and/or diabetes are treated by partially inhibiting circulating leptin in a person in need thereof.

A glucagon derivative, a long-acting conjugate of the glucagon derivative, and a use thereof are disclosed.

A glucagon derivative, a long-acting conjugate of the glucagon derivative, and a use thereof are disclosed.

A peptide and a peptide complex of the present invention exhibit an anti-obesity effect by inhibiting fat accumulation and decomposing already accumulated fat, and exhibit an excellent effect with respect to diabetes by effectively reducing blood sugar. The peptide and the peptide complex of the present invention decrease the expression of PPARγ, ACC, and aP2, which are adipogenic markers, increase the expression of pHSL, AMPK-α1, CGI-58, and ATGL, which are lipolytic factors, and reduce the size of fat cells and blood cholesterol values. The peptide and the peptide complex of the present invention, which have excellent activity and safety, can be advantageously applied to drugs and quasi-drugs.

The present disclosure relates to the identification of Nurr1 as a key regulator of metabolism, and the use of Nurr1 agonist to treat metabolic disorders such as diabetes, obesity, metabolic syndrome and hepatic steatosis.

The present disclosure relates to the identification of Nurr1 as a key regulator of metabolism, and the use of Nurr1 agonist to treat metabolic disorders such as diabetes, obesity, metabolic syndrome and hepatic steatosis.

The present disclosure relates generally to therapeutic agents and related uses thereof, including, agents for reducing leptin in a patient or subject and methods of treatment thereof. The therapeutic agents can comprise (without limitation), an antibody or specific binding fragment thereof, a leptin antagonist, a leptin targeting antisense oligonucleotide, a leptin targeting small interfering RNA (siRNA), a leptin targeting short hairpin RNA (shRNA), and/or a gene editing composition directed to at least one target sequence of a leptin polynucleotide. The therapeutic agents can be used in various methods of treatment, including (without limitation), treating liver fibrosis, cancer, inducing or maintaining weight loss, reducing or preventing weight gain, and increasing insulin sensitivity, among others.

This invention is directed to compositions and methods for the treatment and prevention of hypoglycemic complications. Specifically, aspects of the invention are drawn to the use of leptin for the treatment and prevention of hypoglycemic complications.

This invention is directed to compositions and methods for the treatment and prevention of hypoglycemic complications. Specifically, aspects of the invention are drawn to the use of leptin for the treatment and prevention of hypoglycemic complications.